Filing Details

Accession Number:
0000947871-21-000960
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-25 20:36:58
Reporting Period:
2021-08-23
Accepted Time:
2021-08-25 20:36:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808158 Repare Therapeutics Inc. RPTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1572451 P David Bonita 601 Lexington Avenue
54Th Floor
New York NY 10022-4629
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-08-23 6,885 $34.06 3,249,972 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-08-23 209 $34.06 98,401 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-08-24 3,920 $34.07 3,246,052 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-08-24 119 $34.07 98,282 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-08-25 6,874 $34.34 3,239,178 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-08-25 208 $34.34 98,074 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. These shares of the Issuer's common stock were sold in a block order at price of $34.06 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP ("OPI VII").
  2. These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. The Reporting Person is a member of OrbiMed Advisors. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
  3. These shares of the Issuer's common stock were sold in a block order at price of $34.06 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited ("OPM").
  4. These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.
  5. Each of GP VII, OrbiMed Advisors, OrbiMed Capital, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of GP VII, OrbiMed Advisors, OrbiMed Capital, or the Reporting Person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
  6. These shares of the Issuer's common stock were sold in a block order at price of $34.07 pursuant to a Rule 10b5-1 trading plan established by OPI VII.
  7. These shares of the Issuer's common stock were sold in a block order at price of $34.07 pursuant to a Rule 10b5-1 trading plan established by OPM.
  8. These shares of the Issuer's common stock were sold in a block order at price of $34.34 pursuant to a Rule 10b5-1 trading plan established by OPI VII.
  9. These shares of the Issuer's common stock were sold in a block order at price of $34.34 pursuant to a Rule 10b5-1 trading plan established by OPM.